WorldPingSTAT
STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Brief by WorldPing · Original reporting by STAT
WorldPingFlock operates in more than 5,000 communities across 49 states, and is an $8.3 billion venture darling. Now, the company’s run into trouble.
This is a short WorldPing brief. The full report was published by Fortune.
Read the full report at Fortune
WorldPingThe FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Brief by WorldPing · Original reporting by STAT
WorldPingPiero Cipollone said the Eurosystem would not identify digital euro users as central bank digital currencies face privacy concerns worldwide.
Brief by WorldPing · Original reporting by Cointelegraph